23:54 , Jul 19, 2019 |  BC Extra  |  Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:08 , Apr 15, 2019 |  BC Extra  |  Company News

Management tracks: GW Pharmaceuticals, Aurinia

Cannabinoid company GW Pharmaceuticals plc (NASDAQ:GWPH) hired Darren Cline as chief commercial officer. He succeeds Julian Gangolli who is retiring. Cline was EVP, commercial at Seattle Genetics Inc. (NASDAQ:SGEN). Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) hired...
22:43 , Mar 6, 2019 |  BC Extra  |  Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

UCB Ventures hired Alicia Irurzun-Lafitte as a partner. She was a principal at M Ventures, the corporate venture fund of Merck KGaA (Xetra:MRK). GlycoMimetics Inc. (NASDAQ:GLYC) said Chairman Jim Barrett will retire from the board....
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:11 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Aurinia starts Phase III AURORA trial of voclosporin for lupus nephritis

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) began the Phase III AURORA trial evaluating Luveniq voclosporin (LX211) to treat lupus nephritis. The double-blind, international trial will enroll about 320 patients to receive twice-daily 23.7 mg voclosporin plus...
15:46 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Voclosporin regulatory update

Aurinia said it believes results from the planned Phase III AURORA trial and the completed Phase IIb AURA-LV trial of voclosporin will be sufficient for regulatory submissions of the product in the EU and Japan...
23:42 , Apr 7, 2017 |  BC Extra  |  Company News

Aurinia rises as regulators clarify path for voclosporin

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) said it believes results from a planned Phase III study and a completed Phase IIb study of voclosporin ( LX211 ) will be sufficient for regulatory submissions in the EU...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...